DURYSTA Logo
  • For U.S. Residents Only
  • Prescribing Information
  • Important Safety Information
  • Patient Site
  • HCP Site

Site Map

Site Map

Home

About VUITY®

What Is Presbyopia

FAQs

Healthcare Professional Site

Have questions about VUITY®?

Read FAQs

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
  • You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
  • The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
  • You are allergic to any of its ingredients

DURYSTA may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA may cause increased brown coloring of the iris, which may be permanent.

Eye injections, including DURYSTA, have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.

The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Please see full Prescribing Information.

US-DUR-240150

  • About AbbVie
  • Accessibility Statement
  • Contact Us
  • Terms of Use
  • Privacy Notice
  • Cookies Settings
  • Your Privacy Choices

© 2024 AbbVie. All rights reserved.
All trademarks are the property of their respective owners.
US-DUR-240039

US-VUI-230174

AbbVie logo

My VUITY® Points (MVP) Loyalty Program (the “Program”) Terms, Conditions, and Eligibility Criteria

 

By enrolling in the Program, you ("You") agree to these Terms and Conditions. Available to patients in the United States and Territories of the United States with a prescription for VUITY® who meet eligibility criteria. The Program is not available to patients enrolled in any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time You begin receiving prescription drug coverage under any federal, state, or government-funded healthcare program, or otherwise reside in a jurisdiction where participation is prohibited by law, You will no longer be able to use the Program, will no longer be eligible for any related benefits, and must call 1-844-351-6186 to disenroll from the Program. You may not seek reimbursement for value received from the Program from any third-party payers. The Program is a points accumulation loyalty program administered by RIS Rx on behalf of Allergan, an AbbVie Company (“AbbVie”). The program offers You the opportunity to earn rewards points with eligible VUITY® prescription fills. One VUITY® 2.5 mL prescription fill is equal to 10 points, and one VUITY® 5 mL prescription is equal to 20 points; You may also be eligible to earn points through other promotions from time to time, at AbbVie’s discretion. 40 points may be redeemed for a reward toward one free VUITY® 2.5 mL prescription fill, and 60 points may be redeemed for a reward toward one free VUITY® 5 mL prescription fill. Alternatively, points may also be redeemed earlier for discount vouchers on VUITY® prescription fills, as follows: 10 points for a discount of $10, 20 points for a discount of $20, 30 points for a discount of $40, 40 points for a discount of $79, and 60 points for a discount of $120. Further details are outlined at myvuitypoints.com. Once You have earned 60 reward points, no additional points may be accumulated until a VUITY® reward for a free prescription fill or a discount reward is redeemed. Points do not expire, but are subject to AbbVie’s right to discontinue the Program or change Program terms at any time in its discretion. By enrolling in the Program, You (1) agree to not apply the costs you pay for VUITY® toward any commercial insurance benefit or seek reimbursement for the cost from your insurer; (2) understand that any portion of your VUITY® purchase covered by Program points is not subject to reimbursement by healthcare savings, flexible savings, and other similar accounts; and (3) understand that the information You provide will be used by RIS Rx to contact You by mail, email, phone, or text as needed to administer the Program and such information may be shared with AbbVie. You may opt out of the Program at any time on the myvuitypoints.com website or by texting STOP to 698848 or contacting RIS Rx at 1-844-351-6186. For questions and additional information, call 1-833-MY-VUITY (1-833-698-8489). THE PROGRAM AND THESE TERMS AND CONDITIONS ARE SUBJECT TO CHANGE OR DISCONTINUANCE WITHOUT NOTICE. THIS IS NOT HEALTH INSURANCE.

US-VUI-220363 06/23

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
  • You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
  • The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
  • You are allergic to any of its ingredients

DURYSTA may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA may cause increased brown coloring of the iris, which may be permanent.

Eye injections, including DURYSTA, have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.

The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Please see full Prescribing Information.

US-DUR-240150